← Human Trials & Peer-Reviewed Studies
N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk
Plain-language guide to PMID 29987919 (2018): double-blind randomized controlled trial study of BNP (Nesiritide) in 5081 patients.
Key Facts
- PMID
- 29987919
- Journal
- Diabetes, obesity & metabolism
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Idzerda NMA et al. (10 authors)
- DOI
- 10.1111/dom.13465
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at BNP (Nesiritide).
The researchers conducted a post hoc analysis among 5081 patients with type 2 diabetes mellitus participating in the ALTITUDE trial to investigate whether NTproBNP can predict the effects of additional therapy with aliskiren on cardio-renal endpoints.
Why It Was Studied
Sodium retention and volume overload are the main determinants of poor response to renin-angiotensin-aldosterone system (RAAS) inhibition in patients with diabetes.
Who Took Part
According to the abstract, 5081 patients were involved.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the patients nor the staff measuring them knew who was on BNP (Nesiritide), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the BNP (Nesiritide) group a baseline to be compared against.
What Was Measured
PubMed files the paper under topics including Amides, Antihypertensive Agents, Biomarkers, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies and Fumarates.
Author keywords: clinical trial, diabetes complications and type 2 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide) in 5081 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2018 (Diabetes, obesity & metabolism), a journal based in England.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.